95 research outputs found
‘City of Light’: The Production of Urban Space by the Esoteric Spiritual Community of Damanhur, Italy
Standing genetic variation and the evolution of drug resistance in HIV
Drug resistance remains a major problem for the treatment of HIV. Resistance
can occur due to mutations that were present before treatment starts or due to
mutations that occur during treatment. The relative importance of these two
sources is unknown. We study three different situations in which HIV drug
resistance may evolve: starting triple-drug therapy, treatment with a single
dose of nevirapine and interruption of treatment. For each of these three cases
good data are available from literature, which allows us to estimate the
probability that resistance evolves from standing genetic variation. Depending
on the treatment we find probabilities of the evolution of drug resistance due
to standing genetic variation between 0 and 39%. For patients who start
triple-drug combination therapy, we find that drug resistance evolves from
standing genetic variation in approximately 6% of the patients. We use a
population-dynamic and population-genetic model to understand the observations
and to estimate important evolutionary parameters. We find that both, the
effective population size of the virus before treatment, and the fitness of the
resistant mutant during treatment, are key-parameters that determine the
probability that resistance evolves from standing genetic variation.
Importantly, clinical data indicate that both of these parameters can be
manipulated by the kind of treatment that is used.Comment: 33 pages 6 figure
Differential Epigenetic Regulation of TOX Subfamily High Mobility Group Box Genes in Lung and Breast Cancers
Aberrant cytosine methylation affects regulation of hundreds of genes during cancer development. In this study, a novel aberrantly hypermethylated CpG island in cancer was discovered within the TOX2 promoter. TOX2 was unmethylated in normal cells but 28% lung (nâ=â190) and 23% breast (nâ=â80) tumors were methylated. Expression of two novel TOX2 transcripts identified was significantly reduced in primary lung tumors than distant normal lung (p<0.05). These transcripts were silenced in methylated lung and breast cancer cells and 5-Aza-2-deoxycytidine treatment re-expressed both. Extension of these assays to TOX, TOX3, and TOX4 genes that share similar genomic structure and protein homology with TOX2 revealed distinct methylation profiles by smoking status, histology, and cancer type. TOX was almost exclusively methylated in breast (43%) than lung (5%) cancer, whereas TOX3 was frequently methylated in lung (58%) than breast (30%) tumors. TOX4 was unmethylated in all samples and showed the highest expression in normal lung. Compared to TOX4, expression of TOX, TOX2 and TOX3 in normal lung was 25, 44, and 88% lower, respectively, supporting the premise that reduced promoter activity confers increased susceptibility to methylation during lung carcinogenesis. Genome-wide assays revealed that siRNA-mediated TOX2 knockdown modulated multiple pathways while TOX3 inactivation targeted neuronal development and function. Although these knockdowns did not result in further phenotypic changes of lung cancer cells in vitro, the impact on tissue remodeling, inflammatory response, and cell differentiation pathways suggest a potential role for TOX2 in modulating tumor microenvironment
Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines
Transcription factor 2 gene (TCF2) encodes hepatocyte nuclear factor 1ÎČ (HNF1ÎČ), a transcription factor associated with development and metabolism. Mutation of TCF2 has been observed in renal cell cancer, and by screening aberrantly methylated genes, we have now identified TCF2 as a target for epigenetic inactivation in ovarian cancer. TCF2 was methylated in 53% of ovarian cancer cell lines and 26% of primary ovarian cancers, resulting in loss of the gene's expression. TCF2 expression was restored by treating cells with a methyltransferase inhibitor, 5-aza-2âČdeoxycitidine (5-aza-dC). In addition, chromatin immunoprecipitation showed deacetylation of histone H3 in methylated cells and, when combined with 5-aza-dC, the histone deacetylase inhibitor trichostatin A synergistically induced TCF2 expression. Epigenetic inactivation of TCF2 was also seen in colorectal, gastric and pancreatic cell lines, suggesting general involvement of epigenetic inactivation of TCF2 in tumorigenesis. Restoration of TCF2 expression induced expression of HNF4α, a transcriptional target of HNF1ÎČ, indicating that epigenetic silencing of TCF2 leads to alteration of the hepatocyte nuclear factor network in tumours. These results suggest that TCF2 is involved in the development of ovarian cancers and may represent a useful target for their detection and treatment
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.
In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field
The Art of Destruction: Optimizing Collision Energies in Quadrupole-Time of Flight (Q-TOF) Instruments for Glycopeptide-Based Glycoproteomics
A Phenomenology of Return: Forgiveness and Atonement in Emmanuel Levinas and Abraham Joshua Heschel
A way of remembering the sanctity of the other may inform and guide Christianity towards a more robust dialogical perspective with others. This essay will widen the question for the Christian community by exploring how Judaism remembers those who have been wronged. The methodology is phenomenological in so far as the essay explores the phenomenon of return (teshuva) through the thought of Emmanuel Levinas in dialogue with Abraham Joshua Heschel. When Christianity regards Judaism as a living tradition, instead of a relic, atonement and forgiveness rises to the broader horizon of being ethically relevant in an interreligious context. The real-time teaching (talmud) from righteousness (tzedakah) in Judaism opens opportunities for dialogue with otherness.  This exploration of what forgiveness and atonement may mean in a post-Shoah world for Jews and Christians may only contribute to how dialoguing with otherness is a necessary form of return (teshuva) for all interreligious dialogues.
Getting China and India right: Strategies for leveraging the world's fastest growing economies for global advantage
- âŠ